- Home
- PML vs RGNX Comparison
PML vs RGNX Comparison
Compare PML & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PML
- RGNX
- Stock Information
- Founded
- PML 2002
- RGNX 2008
- Country
- PML United States
- RGNX United States
- Employees
- PML N/A
- RGNX N/A
- Industry
- PML Investment Managers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PML Finance
- RGNX Health Care
- Exchange
- PML Nasdaq
- RGNX Nasdaq
- Market Cap
- PML 478.0M
- RGNX 451.1M
- IPO Year
- PML N/A
- RGNX 2015
- Fundamental
- Price
- PML $7.82
- RGNX $9.03
- Analyst Decision
- PML
- RGNX Strong Buy
- Analyst Count
- PML 0
- RGNX 8
- Target Price
- PML N/A
- RGNX $28.50
- AVG Volume (30 Days)
- PML 188.0K
- RGNX 502.6K
- Earning Date
- PML 01-01-0001
- RGNX 11-05-2025
- Dividend Yield
- PML 5.65%
- RGNX N/A
- EPS Growth
- PML N/A
- RGNX N/A
- EPS
- PML N/A
- RGNX N/A
- Revenue
- PML N/A
- RGNX $155,782,000.00
- Revenue This Year
- PML N/A
- RGNX $203.27
- Revenue Next Year
- PML N/A
- RGNX $0.58
- P/E Ratio
- PML N/A
- RGNX N/A
- Revenue Growth
- PML N/A
- RGNX 74.95
- 52 Week Low
- PML $6.92
- RGNX $5.04
- 52 Week High
- PML $9.46
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- PML 84.90
- RGNX 49.37
- Support Level
- PML $7.46
- RGNX $8.82
- Resistance Level
- PML $7.57
- RGNX $10.08
- Average True Range (ATR)
- PML 0.08
- RGNX 0.54
- MACD
- PML 0.06
- RGNX -0.05
- Stochastic Oscillator
- PML 93.38
- RGNX 25.27
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.